
PLx Pharma PLXP
Quartalsbericht 2022-Q3
hinzugefügt 10.11.2022
PLx Pharma EV 2011-2026 | PLXP
EV Jährlich PLx Pharma
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 73.8 M | 64.4 M | 68.2 M | 44.7 M | 45.5 M | 17.1 M | 72.7 M | 60.7 M | -3.04 M | 162 K | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 73.8 M | -3.04 M | 44.4 M |
EV anderer Aktien in der Arzneimittelhersteller
| Name | EV | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
AcelRx Pharmaceuticals
ACRX
|
6.79 M | - | 7.5 % | $ 6.35 M | ||
|
Adamis Pharmaceuticals Corporation
ADMP
|
28.5 M | - | 0.86 % | $ 117 M | ||
|
Aerie Pharmaceuticals
AERI
|
737 M | - | - | $ 754 M | ||
|
Assertio Holdings
ASRT
|
238 M | $ 19.21 | -3.37 % | $ 123 M | ||
|
Canopy Growth Corporation
CGC
|
459 M | $ 1.0 | 2.63 % | $ 108 M | ||
|
Avadel Pharmaceuticals plc
AVDL
|
756 M | - | - | $ 2.06 B | ||
|
Cronos Group
CRON
|
3.84 B | $ 2.53 | 0.8 % | $ 1.33 B | ||
|
Aurora Cannabis
ACB
|
106 M | $ 3.44 | 2.69 % | $ 86.3 M | ||
|
Catalent
CTLT
|
16.7 B | - | - | $ 11.5 B | ||
|
Agile Therapeutics
AGRX
|
25.3 M | - | 10.11 % | $ 58.2 M | ||
|
Alimera Sciences
ALIM
|
197 M | - | - | $ 142 M | ||
|
China Pharma Holdings
CPHI
|
10.7 M | $ 0.63 | -1.56 % | $ 2.7 M | ||
|
Athenex
ATNX
|
209 M | - | -23.39 % | $ 1.76 M | ||
|
Eagle Pharmaceuticals
EGRX
|
457 M | - | -39.89 % | $ 27.7 M | ||
|
DURECT Corporation
DRRX
|
3.37 M | - | - | $ 50.1 M | ||
|
Emergent BioSolutions
EBS
|
1.2 B | $ 8.23 | -1.79 % | $ 421 M | ||
|
Calliditas Therapeutics AB (publ)
CALT
|
10.2 M | - | -0.1 % | $ 2.03 B | ||
|
Evoke Pharma
EVOK
|
7.15 M | - | - | $ 36.6 M | ||
|
HEXO Corp.
HEXO
|
284 M | - | 2.45 % | $ 38.1 M | ||
|
Cumberland Pharmaceuticals
CPIX
|
124 M | $ 3.17 | 2.26 % | $ 44.6 M | ||
|
Endo International plc
ENDP
|
-710 M | - | - | $ 28.9 M | ||
|
Bausch Health Companies
BHC
|
29.9 B | $ 5.35 | -4.12 % | $ 1.95 B | ||
|
Harrow Health
HROW
|
2.21 B | $ 35.31 | -0.34 % | $ 1.3 B | ||
|
Jupiter Wellness
JUPW
|
3.7 M | - | - | $ 33.6 M | ||
|
Evolus
EOLS
|
467 M | $ 4.03 | -6.5 % | $ 260 M | ||
|
Lannett Company
LCI
|
648 M | - | 1.15 % | $ 7.11 M | ||
|
Neoleukin Therapeutics
NLTX
|
-80.1 M | - | - | $ 193 M | ||
|
OptiNose
OPTN
|
312 M | - | - | $ 1.08 B | ||
|
Organogenesis Holdings
ORGO
|
392 M | $ 2.24 | -3.03 % | $ 295 M | ||
|
Pacira BioSciences
PCRX
|
1.68 B | $ 22.7 | -0.39 % | $ 1.05 B | ||
|
PetIQ
PETQ
|
280 M | - | 1.64 % | $ 400 M | ||
|
Perrigo Company plc
PRGO
|
7.03 B | $ 10.85 | -1.36 % | $ 1.5 B | ||
|
ProPhase Labs
PRPH
|
145 M | - | - | $ 5.07 M | ||
|
Radius Health
RDUS
|
700 M | - | - | $ 1.42 B | ||
|
Relmada Therapeutics
RLMD
|
251 M | $ 6.99 | -1.55 % | $ 276 M | ||
|
Recro Pharma
REPH
|
220 M | - | -4.76 % | $ 65.3 M | ||
|
Rockwell Medical
RMTI
|
43.3 M | $ 0.96 | 2.54 % | $ 34.5 M | ||
|
Sonoma Pharmaceuticals
SNOA
|
7.57 M | $ 2.37 | -2.47 % | $ 2.94 M | ||
|
Solid Biosciences
SLDB
|
616 M | $ 7.49 | 1.49 % | $ 655 M | ||
|
Viatris
VTRS
|
41.3 B | $ 13.44 | -1.39 % | $ 16.1 B | ||
|
cbdMD
YCBD
|
7.85 M | $ 0.73 | 2.37 % | $ 3.15 M | ||
|
Zomedica Corp.
ZOM
|
2.62 M | - | -0.21 % | $ 98 M | ||
|
Zynerba Pharmaceuticals
ZYNE
|
-22.6 M | - | - | $ 55.5 M | ||
|
SCYNEXIS
SCYX
|
26.3 M | $ 0.89 | -0.05 % | $ 44.4 M | ||
|
Tricida
TCDA
|
506 M | - | - | $ 3.25 M | ||
|
OrganiGram Holdings
OGI
|
456 M | $ 1.38 | 2.99 % | $ 402 M | ||
|
TherapeuticsMD
TXMD
|
26.3 M | $ 2.0 | - | $ 23.1 M | ||
|
Sundial Growers
SNDL
|
-17.5 M | $ 1.36 | 2.26 % | $ 3.37 M | ||
|
Tilray
TLRY
|
1.96 B | $ 6.55 | 6.68 % | $ 4.05 B |